2010
Hyperglycemia on admission predicts larger infarct size in patients undergoing percutaneous coronary intervention for acute ST-segment elevation myocardial infarction
Cruz-Gonzalez I, Chia S, Raffel O, Sanchez-Ledesma M, Senatore F, Wackers F, Nathan D, Jang I. Hyperglycemia on admission predicts larger infarct size in patients undergoing percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Diabetes Research And Clinical Practice 2010, 88: 97-102. PMID: 20083319, DOI: 10.1016/j.diabres.2010.01.001.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionAcute ST-segment elevation myocardial infarctionPrimary PCILarger infarct sizeElevation myocardial infarctionPercutaneous coronary interventionInfarct sizeCoronary interventionMyocardial infarctionDay 5Final TIMI 3 flowTIMI 3 flowMultivariate linear regression analysisSingle photon emissionAdmission correlateSTEMI patientsBaseline characteristicsDiabetic statusHyperglycemia groupIndependent predictorsHyperglycemiaPatientsLinear regression analysisAdmission
2008
Association of Leukocyte and Neutrophil Counts With Infarct Size, Left Ventricular Function and Outcomes After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction
Chia S, Nagurney J, Brown D, Raffel O, Bamberg F, Senatore F, Wackers F, Jang I. Association of Leukocyte and Neutrophil Counts With Infarct Size, Left Ventricular Function and Outcomes After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. The American Journal Of Cardiology 2008, 103: 333-337. PMID: 19166685, DOI: 10.1016/j.amjcard.2008.09.085.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionLeft ventricular ejection fractionPrimary PCIST-segment elevation myocardial infarctionElevation myocardial infarctionLarger infarct sizePercutaneous coronary interventionInfarct sizeNeutrophil countMyocardial infarctionElevated leukocytesLeukocyte countCardiac eventsCoronary interventionFirst ST-segment elevation myocardial infarctionAcute Myocardial Infarction StudyST-elevation myocardial infarctionAssociation of leukocytesComposite cardiac eventsIntracellular calcium modulatorsLeft Ventricular SalvageAdverse cardiac eventsElevated leukocyte countPlacebo-controlled trialMyocardial Infarction StudyUtility of Cardiac Biomarkers in Predicting Infarct Size, Left Ventricular Function, and Clinical Outcome After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
Chia S, Senatore F, Raffel O, Lee H, Wackers F, Jang I. Utility of Cardiac Biomarkers in Predicting Infarct Size, Left Ventricular Function, and Clinical Outcome After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. JACC Cardiovascular Interventions 2008, 1: 415-423. PMID: 19463339, DOI: 10.1016/j.jcin.2008.04.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryBenzenesulfonatesBiomarkersCardiovascular AgentsCoronary AngiographyCreatine Kinase, MB FormDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionMyocardiumPiperazinesPredictive Value of TestsProportional Hazards ModelsProspective StudiesRisk AssessmentStroke VolumeTime FactorsTomography, Emission-Computed, Single-PhotonTreatment OutcomeTroponin ITroponin TUnited StatesVentricular Function, LeftConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPrimary PCIElevation myocardial infarctionPercutaneous coronary interventionInfarct sizeClinical outcomesMyocardial infarctionCardiac biomarkersCoronary interventionCreatine kinaseCK-MBLarge ST-segment elevation myocardial infarctionTroponin TIntracellular calcium modulatorsLarger infarct sizeVentricular ejection fractionCardiac biomarker levelsLeft ventricular functionComposite clinical eventsTime-concentration curveEVOLVE trialLower LVEFAdverse eventsEjection fraction
2007
A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE)
Jang I, Weissman N, Picard M, Zile M, Pettigrew V, Shen S, Tatsuno J, Hibberd M, Tzivoni D, Wackers F, Investigators T. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE). American Heart Journal 2007, 155: 113.e1-113.e8. PMID: 18082500, DOI: 10.1016/j.ahj.2007.08.020.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryBenzenesulfonatesCardiac CatheterizationCombined Modality TherapyCoronary AngiographyDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleElectrocardiographyFemaleFollow-Up StudiesHumansInfusions, IntravenousMaleMiddle AgedMyocardial InfarctionPiperazinesProbabilityReference ValuesRisk AssessmentSalvage TherapyStroke VolumeSurvival RateTreatment OutcomeVentricular Function, LeftConceptsPrimary percutaneous coronary interventionLeft ventricular ejection fractionST-elevation myocardial infarctionPrimary PCIMCC-135Percutaneous coronary interventionAcute myocardial infarctionInfarct sizeMyocardial infarctionDay 5Coronary interventionClinical outcomesCalcium overloadPreservation of LVEFAcute ST-elevation myocardial infarctionEnd pointTarget populationComposite clinical outcomeLeft Ventricular SalvagePlacebo-controlled studyPrimary end pointSecondary end pointsLow-dose groupVentricular ejection fractionHigh-dose group
2005
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: Rationale and Design of the Evaluation of MCC-135 for Left Ventricular Salvage in Acute MI (EVOLVE) Study
Jang I, Pettigrew V, Picard M, Kowey P, Demmel V, Zile M, Tatsuno J, Wackers F, Hibberd M. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: Rationale and Design of the Evaluation of MCC-135 for Left Ventricular Salvage in Acute MI (EVOLVE) Study. Journal Of Thrombosis And Thrombolysis 2005, 20: 147-153. PMID: 16261287, DOI: 10.1007/s11239-005-3267-4.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdultAngioplasty, Balloon, CoronaryBenzenesulfonatesCalciumDouble-Blind MethodEchocardiographyHumansMaleMiddle AgedMuscle CellsMyocardial InfarctionMyocardial Reperfusion InjuryNecrosisPiperazinesRadiographyTomography, Emission-Computed, Single-PhotonVentricular Function, LeftConceptsPrimary percutaneous coronary interventionST-elevation myocardial infarctionLeft Ventricular SalvageElevation myocardial infarctionPlacebo-controlled clinical trialMCC-135Percutaneous coronary interventionIntracellular calcium overloadMyocardial infarctionPost-myocardial infarctionVentricular functionCalcium overloadEVOLVE studyCoronary interventionAdjunct therapyInfarct sizeClinical trialsPrimary PCIAcute ST-elevation myocardial infarctionMI studiesVentricular ejection fractionSerum cardiac markersAcute myocardial infarctionEarly clinical studiesMyocardial infarction size
1994
Effects of altered left ventricular geometry on quantitative technetium 99m sestamibi defect size in humans: Perfusion imaging during coronary angioplasty
Haronian H, Sinusas A, Remetz M, Brennan J, Cabin H, Zaret B, Wackers F. Effects of altered left ventricular geometry on quantitative technetium 99m sestamibi defect size in humans: Perfusion imaging during coronary angioplasty. Journal Of Nuclear Cardiology 1994, 1: 150-158. PMID: 9420682, DOI: 10.1007/bf02984087.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngioplasty, Balloon, CoronaryElectrocardiographyFemaleHeartHumansMaleMiddle AgedMyocardial ContractionRadionuclide ImagingTechnetium Tc 99m SestamibiVentricular Function, LeftConceptsPercutaneous transluminal coronary angioplastyLeft ventricular geometryAltered left ventricular geometryCoronary angioplastyRegional wall motionVentricular geometryEnd-diastolic imagesMyocardial perfusionExercise-induced myocardial ischemiaAbnormal regional wall motionMyocardial risk areaTransluminal coronary angioplastyQuantitative defectsExperimental animal modelsPlanar myocardial perfusionMyocardial perfusion imagingQuantitative technetiumResultsNine patientsVentricular functionCoronary arteryMyocardial infarctionVessel occlusionMyocardial ischemiaPerfusion defectsWall motion
1993
Myocardial risk area defined by technetium-99m sestamibi imaging during percutaneous transluminal coronary angioplasty: Comparison with coronary angiography
Haronian H, Remetz M, Sinusas A, Baron J, Miller H, Cleman M, Zaret B, Wackers F. Myocardial risk area defined by technetium-99m sestamibi imaging during percutaneous transluminal coronary angioplasty: Comparison with coronary angiography. Journal Of The American College Of Cardiology 1993, 22: 1033-1043. PMID: 8409038, DOI: 10.1016/0735-1097(93)90413-u.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryClinical ProtocolsCollateral CirculationCoronary AngiographyCoronary DiseaseEvaluation Studies as TopicFemaleHumansMaleMiddle AgedMyocardial InfarctionObserver VariationPredictive Value of TestsPrognosisReproducibility of ResultsRisk FactorsSeverity of Illness IndexTechnetium Tc 99m SestamibiTomography, Emission-Computed, Single-PhotonConceptsMyocardial risk areaCoronary angiographyCoronary angioplastyQuantitative myocardial perfusionMyocardial perfusionMyocardial areaPercutaneous transluminal coronary angioplastyAngiographic risk scoresSmall risk areasTransluminal coronary angioplastyCoronary artery diseaseCoronary artery stenosisInitial myocardial uptakeAngioplasty balloon inflationArtery diseaseLeft anteriorNonperfused areaArtery stenosisCoronary anatomyCoronary arteryBalloon inflationPatient managementMyocardial uptakeRisk scoreAngioplastyNuclear Cardiology
Zaret B, Wackers F. Nuclear Cardiology. New England Journal Of Medicine 1993, 329: 775-783. PMID: 8350888, DOI: 10.1056/nejm199309093291107.Peer-Reviewed Original ResearchFrequency and significance of right ventricular dysfunction during inferior wall left ventricular myocardial infarction treated with thrombolytic therapy (results from the Thrombolysis in Myocardial Infarction [TIMI] II trial)
Berger P, Ruocco N, Ryan T, Jacobs A, Zaret B, Wackers F, Frederick M, Faxon D, Group R. Frequency and significance of right ventricular dysfunction during inferior wall left ventricular myocardial infarction treated with thrombolytic therapy (results from the Thrombolysis in Myocardial Infarction [TIMI] II trial). The American Journal Of Cardiology 1993, 71: 1148-1152. PMID: 8097614, DOI: 10.1016/0002-9149(93)90637-r.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAngioplasty, Balloon, CoronaryCombined Modality TherapyConstriction, PathologicCoronary VesselsFemaleHeart DiseasesHeart VentriclesHumansMaleMiddle AgedMyocardial InfarctionRadionuclide VentriculographyThrombolytic TherapyTissue Plasminogen ActivatorVentricular Function, LeftVentricular Function, RightConceptsRV wall motion abnormalitiesRight ventricular dysfunctionRV dysfunctionVentricular myocardial infarctionWall motion abnormalitiesVentricular dysfunctionThrombolytic therapyRadionuclide ventriculographyMyocardial infarctionMotion abnormalitiesInferior wallLower mean left ventricular ejection fractionMean left ventricular ejection fractionLeft ventricular ejection fractionBaseline clinical characteristicsInfarct-related arteryMyocardial Infarction (TIMI) II trialVentricular ejection fractionEquilibrium radionuclide ventriculographyHospital complicationsMultivessel diseaseII trialClinical characteristicsHospital dischargeEjection fraction
1991
Validation of continuous radionuclide left ventricular functioning monitoring in detecting silent myocardial ischemia during balloon angioplasty of the left anterior descending coronary artery
Kayden D, Remetz M, Cabin H, Deckelbaum L, Cleman M, Wackers F, Zaret B. Validation of continuous radionuclide left ventricular functioning monitoring in detecting silent myocardial ischemia during balloon angioplasty of the left anterior descending coronary artery. The American Journal Of Cardiology 1991, 67: 1339-1343. PMID: 2042565, DOI: 10.1016/0002-9149(91)90462-t.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCoronary DiseaseElectrocardiography, AmbulatoryHumansMaleMiddle AgedRadionuclide VentriculographyStroke VolumeVentricular Function, LeftConceptsSilent myocardial ischemiaLV ejection fractionLV dysfunctionMyocardial ischemiaEjection fractionLV functionBalloon inflationRelative end-systolic volumeTransient ST-segment depressionPercutaneous transluminal coronary angioplastyMean LV ejection fractionST-segment depressionContinuous electrocardiographic monitoringTransluminal coronary angioplastyLeft ventricular functionST-segment changesEnd-diastolic volumeEnd-systolic volumeIschemic decreaseCoronary angioplastyVentricular functionElectrocardiographic changesElectrocardiographic monitoringBalloon angioplastyCoronary artery
1990
Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial.
Rogers W, Baim D, Gore J, Brown B, Roberts R, Williams D, Chesebro J, Babb J, Sheehan F, Wackers F. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial. Circulation 1990, 81: 1457-1476. PMID: 2110033, DOI: 10.1161/01.cir.81.5.1457.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCombined Modality TherapyCoronary AngiographyCoronary Artery BypassExercise TestFemaleHumansMaleMiddle AgedMyocardial InfarctionRadionuclide VentriculographyRandomized Controlled Trials as TopicStroke VolumeThrombolytic TherapyTime FactorsTissue Plasminogen ActivatorConceptsCoronary artery bypass graft surgeryPercutaneous transluminal coronary angioplastyInvasive strategy groupConservative-strategy groupAcute myocardial infarctionTreatment groupsPrimary study end pointResidual infarct artery stenosisArtery bypass graft surgeryPatent infarct-related arteryImmediate invasive strategyPredischarge exercise testingSimilar cumulative ratesBypass graft surgeryStudy end pointInfarct-related arteryTransluminal coronary angioplastyVentricular ejection fractionInitial management strategyLong-term outcomesConservative strategyStrategy groupTissue-type plasminogen activatorNonfatal reinfarctionGraft surgery